R1 RCM (NASDAQ:RCM) Earns Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of R1 RCM (NASDAQ:RCM) in a research note published on Tuesday, Benzinga reports. They currently have a $14.30 price target on the healthcare provider’s stock.

Several other research analysts also recently commented on the company. Leerink Partnrs downgraded R1 RCM from a strong-buy rating to a hold rating in a report on Thursday, August 1st. Robert W. Baird restated an outperform rating and set a $18.00 price target on shares of R1 RCM in a research note on Tuesday, July 2nd. TD Cowen reaffirmed a hold rating and issued a $14.30 price objective (down from $20.00) on shares of R1 RCM in a research note on Monday, August 5th. Royal Bank of Canada reiterated an outperform rating and set a $19.00 target price on shares of R1 RCM in a report on Friday, June 28th. Finally, Stephens lowered shares of R1 RCM from an overweight rating to an equal weight rating in a report on Thursday, August 1st. Thirteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of Hold and an average target price of $15.41.

R1 RCM Stock Down 0.3 %

NASDAQ:RCM opened at $14.04 on Tuesday. The company has a market cap of $5.91 billion, a price-to-earnings ratio of -175.50 and a beta of 0.85. R1 RCM has a twelve month low of $8.87 and a twelve month high of $18.22. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The stock has a fifty day simple moving average of $13.03 and a 200-day simple moving average of $12.67.

R1 RCM (NASDAQ:RCM) last announced its quarterly earnings data on Wednesday, August 7th. The healthcare provider reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $627.90 million during the quarter, compared to analyst estimates of $633.10 million. R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. The business’s revenue was up 12.0% compared to the same quarter last year. Analysts anticipate that R1 RCM will post -0.2 EPS for the current year.

Hedge Funds Weigh In On R1 RCM

Several hedge funds have recently modified their holdings of RCM. Capital International Investors increased its position in shares of R1 RCM by 0.8% in the 4th quarter. Capital International Investors now owns 8,343,199 shares of the healthcare provider’s stock valued at $88,188,000 after acquiring an additional 67,485 shares during the period. Norges Bank acquired a new position in shares of R1 RCM in the fourth quarter valued at about $42,539,000. P2 Capital Partners LLC lifted its holdings in shares of R1 RCM by 70,366.3% during the fourth quarter. P2 Capital Partners LLC now owns 3,535,294 shares of the healthcare provider’s stock worth $37,368,000 after purchasing an additional 3,530,277 shares during the period. Dimensional Fund Advisors LP boosted its position in R1 RCM by 4.5% in the second quarter. Dimensional Fund Advisors LP now owns 3,154,888 shares of the healthcare provider’s stock valued at $39,624,000 after buying an additional 136,808 shares during the last quarter. Finally, Boston Partners boosted its holdings in shares of R1 RCM by 4,976.6% in the 1st quarter. Boston Partners now owns 2,570,371 shares of the healthcare provider’s stock valued at $32,784,000 after acquiring an additional 2,519,739 shares during the last quarter. Institutional investors and hedge funds own 61.10% of the company’s stock.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.